where diverse natural CDRs are combined into an antibody framework 11, using only CDR-encoding gene fragments originating from sequences formed and “proofread” in vivo. Such proofread peptide ...

In the landmark Amgen v. Sanofi case (previously covered here), the Supreme Court affirmed that patent claims drawn to a genus of ...

The Global Multiple Sclerosis Drugs Market achieved a valuation of $23.2 Billion in 2024 and is anticipated to exceed $53.25 ...

Amgen's strategic growth through M&A and R&D investments has led to a diversified portfolio. Find out why I give AMGN stock a ...

Valneva receives Brazilian marketing authorization for single-dose vaccine Ixchiq for prevention of disease caused by chikungunya virus: Saint Herblain, France Wednesday, April 16 ...

ParaScript, an AI-powered document processing company, announced today their partnership with Endurance Italia Srl, a leader in Intelligent Document Processing (IDP) solutions. Through this ...

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company today announced that the Brazilian Health Regulatory Agency (ANVISA) has granted marketing authorization to its single-dose ...

They've all dosed multiple cohorts of patients and we actually have some very exciting preclinical assets like our antibody drug conjugates ... to Japan and Taiwan, regions where 33% to 40% ...

Genome Research ( ) publishes a second special issue highlighting advances in long-read sequencing applications in ...

Zymeworks Inc., a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, ...